|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines.
|
30870485 |
2019 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We established N-myc-downregulated IMR-32 cells using shRNA lentiviral particles targeting N-myc and examined the effect the N-myc inhibition on TRAIL susceptibility in human neuroblastoma IMR-32 cells expressing caspase-8.
|
30724400 |
2019 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study unveils a novel mechanism for the TRAIL-induced apoptosis of TrkAIII expressing NB cells that depends upon SHP/Src-mediated crosstalk between the TRAIL-receptor signaling pathway and TrkAIII, and supports a novel potential pro-apoptotic therapeutic use for TRAIL in TrkAIII expressing NB.
|
27821809 |
2016 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PI3K inhibitor PI103 cooperates with TRAIL to synergistically induce apoptosis (combination index < 0.1), to suppress clonogenic survival, and to reduce tumor growth in a neuroblastoma in vivo model.
|
21355080 |
2011 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, combined treatment with sodium arsenite and TRAIL or simvastatin and TRAIL efficiently induced apoptotic commitment in human neuroblastoma cells.
|
21910007 |
2011 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
By demonstrating that NF-kappaB inhibition sensitizes neuroblastoma cells for TRAIL-induced apoptosis, our findings have important implications.
|
19065652 |
2009 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It has been reported that neuroblastoma cells with MYCN amplification are unable to start TRAIL-dependent death and MYCN, in concert with cytotoxic drugs, efficiently induces the mitochondrial pathway of apoptosis through oxidative mechanisms.
|
17991446 |
2008 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells.
|
17479107 |
2007 |
|
Neuroblastoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Thus, by demonstrating that 5-dAzaC and IFN-gamma at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.
|
16607283 |
2006 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
|
16863850 |
2006 |
|
Neuroblastoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The results of the present study show that the anti-diabetic drug troglitazone sensitizes human glioma and neuroblastoma cells to TRAIL-induced apoptosis.
|
16820965 |
2006 |
|
Neuroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, by demonstrating that 5-dAzaC and IFN-gamma at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.
|
16607283 |
2006 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to determine whether the phosphatidylinositol 3-kinase (PI3K)/Akt pathway can alter the expression of survivin and facilitate tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in neuroblastoma cells.
|
15065019 |
2004 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TRAIL-mediated cell death was enhanced when neuroblastoma cells were simultaneously infected with a dominant-negative mutant of IkappaB kinase, a kinase essential for NF-kappaB activation.
|
15332116 |
2004 |
|
Neuroblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Recently aberrant methylation of TRAIL decoy receptors was reported in pediatric tumor cell lines and neuroblastomas.
|
14999791 |
2004 |
|
Neuroblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We recently found hypermethylation of the four TRAIL receptors in 9 neuroblastoma cell lines.
|
14506696 |
2003 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This additional lesion in the TRAIL path is because of a loss of cell membrane TRAIL receptors (TR1/TR2) not only in cell lines but in most of the NB tumor tissues evaluated.
|
12615731 |
2003 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report that overexpression of Bcl-2 conferred protection against TRAIL in neuroblastoma, glioblastoma or breast carcinoma cell lines.
|
11948412 |
2002 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because combined treatment also augmented the bystander cell kill, the addition of TRAIL may increase the efficacy of TK/GCV gene therapy of neuroblastoma.
|
11960288 |
2002 |
|
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enhanced levels of ceramide may be involved in apoptosis signaling following stroke since exogenously added synthetic C2-ceramide increased expression of c-jun and the death-inducing ligands (DILs) CD95-L, TRAIL and TNF-alpha in neuroblastoma cells.
|
10224298 |
1999 |